Key clinical point: One-year follow-up of on-label stenting of intracranial arteries showed a suggestion of efficacy.
Major finding: The death or stroke rate was 9% after intracranial stent placement, compared with a 12% rate in historical controls.
Study details: WOVEN, an extended follow-up of 129 patients enrolled in the WEAVE multicenter, randomized study.
Disclosures: WEAVE was sponsored by Stryker Neurovascular, the company that markets the Wingspan intracranial artery stent. WOVEN received no commercial funding. Dr. Alexander has been a consultant to Stryker Neurovascular.
Alexander MJ et al. ISC 2020, Abstract LB4.